Home > Insider Trading > Filing (0001209191-17-042042)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510580	Kite Pharma Inc.	KITE	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222082	M Cynthia Butitta	C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-06-23	5,000	$1.35	122,795	No	4	M	Direct
Common Stock	Disposition	2017-06-23	2,950	$100.54	119,845	No	4	S	Direct
Common Stock	Disposition	2017-06-23	2,050	$101.19	117,795	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2017-06-23	5,000	$0.00	5,000	$1.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
110,394		2024-03-25	No	4	M	Direct

Footnotes

This report is being amended to include the same day exercise of an option that was inadvertently omitted from the initial Form 4 filing.
These sales, although previously reported, are being included in this amendment simply to reflect the correct end of period holdings as a result of the option exercise reflected herein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.01 to $101.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter.